Orchid Pharma partners with Cipla to launch antibiotic in India

4 July 2024

Chennai, India-based Orchid Pharma has announced the launch of its new drug - cefepime-enmetazobactam, which has been approved for the treatment of complicated urinary tract infections (cUTI), hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) indications.

In a landmark collaboration, Orchid Pharma has partnered with India’s Cipla Limited (BSE: 500087) to ensure widespread and rapid distribution of this breakthrough antibiotic combination across India. Orchid claims to be the only Indian pharmaceutical company to have ever invented a New Chemical Entity (NCE),

The partnership between Orchid Pharma and Cipla combines Orchid's innovative drug development capabilities with Cipla's extensive distribution network and market presence. This collaboration aims to ensure that this life-saving medication reaches healthcare providers across India as quickly and efficiently as possible.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK